MTOR and nonpapillary renal cell carcinoma: Zhan et al. (Zhan et al., 2023) elucidated that METTL3 augments GLUT1 expression, thereby accelerating ccRCC progression and conferring resistance to mammalian target of rapamycin (mTOR) inhibitors.